ADA and inflammatory bowel disease: Hence, the aim of this work was to provide an overview of published infliximab population pharmacokinetic models for patients with IBD as well as to evaluate and compare model performance with a focus on differences between ADA-negative and ADA-positive subpopulations in a Bayesian forecasting setting using an external data set.